Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Drug Profile

Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Alternative Names: Cytotoxic T-cell therapy - HengRui YuanZheng; Dendritic cell therapy - HengRui YuanZheng; MASCT I; MASCT-1; Multiple target antigen stimulating cell therapy-I; Multiple-antigen specific cell therapy-I; Neo-MASCT

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Jan 2018 SYZ Cell Therapy plans a phase I trial for Gastric Cancer (Late-stage disease, Second-line or greater therapy) in January 2018 , (NCT03393416)
  • 31 Oct 2017 Shenzhen Second People's Hospital plans a clinical trial for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in China in December 2017 (ChiCTR-ONC-17013136)
  • 06 Jul 2017 HengRui YuanZheng Bio-Technology plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (NCT03205930)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top